Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

MK-1045 · CN201

Bispecific antibody · Immune activation, directed at CD19 and CD3 (CD3E) · developed by Merck &

Phase 2/3 Most advanced trial

MRK Developer

1 Registered trials

What is MK-1045?

MK-1045 is an IgG4 bispecific T-cell engager that binds CD19 on tumor cells and CD3 on T-cells. By cross-linking the two cell types, it induces a cytotoxic T-lymphocyte response against CD19-expressing cells. It is being studied in B-cell acute lymphoblastic leukemia.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: CN201
Drug type: Bispecific antibody
Targets: CD19, CD3 (CD3E)
Mechanism: Immune activation, directed at CD19 and CD3 (CD3E)
Pathways: T-cell cross-linking with tumor cells, cytotoxic T-lymphocyte response
Therapy area: Oncology
Developer: Merck & Co. (MRK)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2/3

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07570173	Phase 2/3	B-cell Acute Lymphoblastic Leukemia	Recruiting	MRK

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

B-cell Acute Lymphoblastic Leukemia

Other drugs acting on CD19 / CD3E

Anti-Thymocyte Globulin FDA approved Blinatumomab FDA approved Inebilizumab FDA approved Loncastuximab tesirine FDA approved AZD5492 Phase 1/2 Budoprutug Phase 1/2 CT-95 Phase 1 Foralumab Phase 2 Gocatamig Phase 1/2 Imvotamab Phase 1/2 Mipletamig Phase 1 Odronextamab Phase 2/3

More from Merck &

BCG Live FDA approved Belzutifan FDA approved Berahyaluronidase Alfa FDA approved Berahyaluronidase Alfa and Pembrolizumab FDA approved Enlicitide FDA approved Ensifentrine FDA approved Letermovir FDA approved Pembrolizumab FDA approved Probenecid FDA approved Alimatravir Phase 2 Bomedemstat Phase 2/3 Calderasib Phase 3

Sources

Updated Oct 8, 2026. Something wrong or missing? Report it on the MRK page.

Follow MRK, the company behind MK-1045

See MRK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

MRK catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z